Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Among authors: zitvogel l. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.
Dendritic cell-based immunotherapy of cancer.
Zitvogel L, Angevin E, Tursz T. Zitvogel L, et al. Ann Oncol. 2000;11 Suppl 3:199-205. doi: 10.1093/annonc/11.suppl_3.199. Ann Oncol. 2000. PMID: 11079142 Free article. Review. No abstract available.
Exosomes for cancer immunotherapy.
Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L. Andre F, et al. Among authors: zitvogel l. Ann Oncol. 2004;15 Suppl 4:iv141-4. doi: 10.1093/annonc/mdh918. Ann Oncol. 2004. PMID: 15477298 Free article. Review. No abstract available.
Prospects for exosomes in immunotherapy of cancer.
Mignot G, Roux S, Thery C, Ségura E, Zitvogel L. Mignot G, et al. Among authors: zitvogel l. J Cell Mol Med. 2006 Apr-Jun;10(2):376-88. doi: 10.1111/j.1582-4934.2006.tb00406.x. J Cell Mol Med. 2006. PMID: 16796806 Free PMC article. Review.
Witch hunt against tumor cells enhanced by dendritic cells.
Locher C, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Kroemer G, Zitvogel L. Locher C, et al. Among authors: zitvogel l. Ann N Y Acad Sci. 2009 Sep;1174:51-60. doi: 10.1111/j.1749-6632.2009.04940.x. Ann N Y Acad Sci. 2009. PMID: 19769736
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.
Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L. Conforti R, et al. Among authors: zitvogel l. Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068181
Dendritic cell-derived exosomes for cancer immunotherapy: what's next?
Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Viaud S, et al. Among authors: zitvogel l. Cancer Res. 2010 Feb 15;70(4):1281-5. doi: 10.1158/0008-5472.CAN-09-3276. Epub 2010 Feb 9. Cancer Res. 2010. PMID: 20145139 Review.
Desirable cell death during anticancer chemotherapy.
Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, Zitvogel L. Locher C, et al. Among authors: zitvogel l. Ann N Y Acad Sci. 2010 Oct;1209:99-108. doi: 10.1111/j.1749-6632.2010.05763.x. Ann N Y Acad Sci. 2010. PMID: 20958322 Review.
578 results